Scholarlink

<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a rapidly increasing global health concern that is interconnected with obesity and metabolic dysregulation. Adipokines, particularly adiponectin and leptin, plays a vital role in the metabolic dysregulation, but their involvement in the MASLD remains incompletely understood. To explore the role of adiponectin and leptin, ratio in MASLD and their potential as biomarkers of liver disease severity. A hospital-based case-control study was conducted that included 200 eligible participants (100 MASLD patients and 100 matched controls). Clinical, anthropometric, demographic characteristics were documented in a structured questionnaire. Biochemical parameters were analyzed on a fully automated biochemistry analyzer, while Adipokines were quantified by using commercially available ELISA kits, Statistical analysis was performed on R software and Stata software (version 17, StataCorp, College Station, TX). MASLD patients exhibited higher BMI and other central obesity indices as compared to controls (<i>p</i> &lt; 0.05). Adiponectin levels were significantly lower, while leptin levels were significantly higher in MASLD patients (<i>p</i> &lt; 0.05). Adiponectin showed negative correlation with obesity and glycemic parameters, whereas leptin demonstrated positive correlations with these parameters (<i>p</i> &lt; 0.05). Leptin levels increased significantly with increasing grade of MASLD (<i>p</i> &lt; 0.05), while adiponectin showed a non-significant decreasing trend. ROC curve analysis showed a moderate diagnostic performance for leptin (AUC = 0.701. Multivariable logistic regression demonstrated BMI and glycemic parameters as independent predictors of MASLD. Adipokine dysregulation, characterized by decreased adiponectin and increased leptin levels, is associated with MASLD. Leptin, in particular, may have a potential as a biomarker for liver disease severity. Furthermore, BMI, central obesity indices, and glycemic parameters are the key players in the pathogenesis of MASLD. These findings highlight the role of metabolic pathways in MASLD pathogenesis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adipokine Dysregulation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Hospital-Based Case–Control Study from India

  • 期刊论文

  • 发表日期：

    2026年5月29日

查看全文
  • Manzoor Ahmad Raina,
  • Karanpreet Bhutani,
  • Gowhar Rashid,
  • Mushtaq Ahmad Khan,
  • Syed Mudassar

摘要

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a rapidly increasing global health concern that is interconnected with obesity and metabolic dysregulation. Adipokines, particularly adiponectin and leptin, plays a vital role in the metabolic dysregulation, but their involvement in the MASLD remains incompletely understood. To explore the role of adiponectin and leptin, ratio in MASLD and their potential as biomarkers of liver disease severity. A hospital-based case-control study was conducted that included 200 eligible participants (100 MASLD patients and 100 matched controls). Clinical, anthropometric, demographic characteristics were documented in a structured questionnaire. Biochemical parameters were analyzed on a fully automated biochemistry analyzer, while Adipokines were quantified by using commercially available ELISA kits, Statistical analysis was performed on R software and Stata software (version 17, StataCorp, College Station, TX). MASLD patients exhibited higher BMI and other central obesity indices as compared to controls (p < 0.05). Adiponectin levels were significantly lower, while leptin levels were significantly higher in MASLD patients (p < 0.05). Adiponectin showed negative correlation with obesity and glycemic parameters, whereas leptin demonstrated positive correlations with these parameters (p < 0.05). Leptin levels increased significantly with increasing grade of MASLD (p < 0.05), while adiponectin showed a non-significant decreasing trend. ROC curve analysis showed a moderate diagnostic performance for leptin (AUC = 0.701. Multivariable logistic regression demonstrated BMI and glycemic parameters as independent predictors of MASLD. Adipokine dysregulation, characterized by decreased adiponectin and increased leptin levels, is associated with MASLD. Leptin, in particular, may have a potential as a biomarker for liver disease severity. Furthermore, BMI, central obesity indices, and glycemic parameters are the key players in the pathogenesis of MASLD. These findings highlight the role of metabolic pathways in MASLD pathogenesis.